TLR4 and cardiac hypertrophy: Overall, these results suggest that the TLR4/MyD88/NF-κB pathway is a bridge between RAS, SNS and hypertension, and provides a novel treatment therapeutic for hypertension and cardiac hypertrophy caused by hypertension.